

Table 1 Comparison of biodistribution results in KM mice between ^{68}Ga -DOTA-FAPI-04 and Al^{18}F -NOTA-FAPI

Organ	^{68}Ga -DOTA-FAPI-04	Al^{18}F -NOTA-FAPI	P value	Significance
Blood	3.94 ± 0.94	1.15 ± 0.10	0.0068	**
Heart	1.35 ± 0.24	0.71 ± 0.31	0.0497	*
Liver	1.01 ± 0.26	0.47 ± 0.02	0.0224	*
Spleen	0.90 ± 0.12	0.27 ± 0.04	0.0009	***
Lung	2.15 ± 0.37	0.71 ± 0.07	0.0027	**
Kidney	2.12 ± 0.22	1.10 ± 0.22	0.0048	**
Stomach wall	1.60 ± 0.15	0.36 ± 0.05	0.0002	***
Small intestine	1.72 ± 0.40	0.86 ± 0.13	0.0245	*
Large intestine	2.21 ± 0.20	0.63 ± 0.15	0.0004	***
Muscle	5.05 ± 1.07	1.25 ± 0.47	0.0048	**
Bone	10.45 ± 2.27	6.34 ± 0.98	0.0451	*
Brain	0.17 ± 0.00	0.08 ± 0.00	<0.0001	****

* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001

Table 2 Human organ radiation dosimetry estimation of Al^{18}F -NOTA-FAPI in adult female patients using OLINDA/EXM 1.0

Target Organ	Absorbed Dose
Adrenals	1.36E-02
Brain	3.98E-03
Breasts	1.06E-02
Gallbladder Wall	1.47E-02
LLI Wall	1.54E-02
Small Intestine	1.43E-02

Stomach Wall	1.27E-02
ULI Wall	1.48E-02
Heart Wall	9.18E-03
Kidneys	1.03E-02
Liver	7.06E-03
Lungs	8.11E-03
Muscle	9.23E-03
Ovaries	1.46E-02
Pancreas	1.38E-02
Red Marrow	1.80E-02
Osteogenic Cells	2.47E-02
Skin	9.28E-03
Spleen	7.43E-03
Thymus	1.28E-02
Thyroid	1.18E-02
UB Wall	1.18E-02
Uterus	1.46E-02
Total body	1.28E-02
Effective dose (mSv/MBq)	1.24E-02

Table 3 Demographic information of cancer patients enrolled in this study

Patient No.	Sex	Age (y)	Weight (kg)	Injected dose(MBq)	Cancer type
1	F	66	60	256.8	Colon Ca.
2	F	72	59	227.9	Lung Ca.
3	M	69	80	173.5	Colon Ca.
4	F	54	65	186.5	Lung Ca.
5	F	64	60	173.5	Pancreas Ca.
6	F	58	70	191.7	Lung Ca.
7	M	55	63	196.8	Lung Ca.
8	F	59	81	217.2	Lung Ca.

9	M	75	68	159.1	Lymphoma
10	M	64	71	187.6	Prostate Ca.
